[Skip to Navigation]
Sign In
Figure 1. Flow of Participants Through the Study
Figure 1. Flow of Participants Through the Study

CABG indicates coronary artery bypass graft; MI, myocardial infarction; PCI, percutaneous coronary intervention.

Figure 2. Geographic Variation of Rates of Stress Testing Prior to Elective Percutaneous Coronary Intervention by Health Referral Region
Figure 2. Geographic Variation of Rates of Stress Testing Prior to Elective Percutaneous Coronary Intervention by Health Referral Region

Stress testing rates range from 22.1% to 70.6%, with a national mean of 44.5% (interquartile range, 30.9%-50.9%). Individual hospital referral region rates were converted into rate ratios based on the national mean. Hospital referral regions with less than 25 percutaneous coronary interventions in the 20% sample were excluded from the analysis (gray).

Figure 3. Factors Predicting Receipt of Stress Test Prior to Elective Percutaneous Coronary Intervention (PCI)
Figure 3. Factors Predicting Receipt of Stress Test Prior to Elective Percutaneous Coronary Intervention (PCI)

Results from a multivariate mixed-effects model adjusting for patient and physician characteristics and hospital referral regions. AOR indicates adjusted odds ratio; CI, confidence interval; and COPD, chronic obstructive pulmonary disease. Error bars indicate 95% CIs.

Table 1. Characteristics of Medicare Patients Undergoing Elective Percutaneous Coronary Intervention in 2004 (N = 23887)
Table 1. Characteristics of Medicare Patients Undergoing Elective Percutaneous Coronary Intervention in 2004 (N = 23887)
Table 2. Physician and Hospital Characteristics of Medicare Patients Undergoing Elective Percutaneous Coronary Intervention (PCI) in 2004 (N = 23887)
Table 2. Physician and Hospital Characteristics of Medicare Patients Undergoing Elective Percutaneous Coronary Intervention (PCI) in 2004 (N = 23887)
1.
Rosamond W, Flegal K, Friday G,  et al.  Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.  Circulation. 2007;115(5):e69-e17117194875PubMedGoogle ScholarCrossref
2.
Lucas FL, DeLorenzo MA, Siewers AE, Wennberg DE. Temporal trends in the utilization of diagnostic testing and treatments for cardiovascular disease in the United States, 1993-2001.  Circulation. 2006;113(3):374-37916432068PubMedGoogle ScholarCrossref
3.
Boden WE, O'Rourke RA, Teo KK,  et al.  Optimal medical therapy with or without PCI for stable coronary disease.  N Engl J Med. 2007;356(15):1503-151617387127PubMedGoogle ScholarCrossref
4.
Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: a meta-analysis of randomised controlled trials.  BMJ. 2000;321(7253):73-7710884254PubMedGoogle ScholarCrossref
5.
Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus medical therapy in nonacute coronary artery disease.  Circulation. 2005;111(22):2906-291215927966PubMedGoogle ScholarCrossref
6.
Folland ED, Hartigan PM, Parisi AF.Veterans Affairs ACME Investigators.  Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial.  J Am Coll Cardiol. 1997;29(7):1505-15119180111PubMedGoogle ScholarCrossref
7.
Pitt B, Waters D, Brown WV,  et al; Atorvastatin versus Revascularization Treatment Investigators.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.  N Engl J Med. 1999;341(2):70-7610395630PubMedGoogle ScholarCrossref
8.
Henderson RA, Pocock SJ, Clayton TC,  et al.  Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy.  J Am Coll Cardiol. 2003;42(7):1161-117014522473PubMedGoogle ScholarCrossref
9.
Hueb W, Lopes NH, Gersh BJ,  et al.  Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.  Circulation. 2007;115(9):1082-108917339566PubMedGoogle ScholarCrossref
10.
Hueb W, Soares PR, Gersh BJ,  et al.  The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results.  J Am Coll Cardiol. 2004;43(10):1743-175115145093PubMedGoogle ScholarCrossref
11.
Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.  N Engl J Med. 2007;356(10):1009-101917296822PubMedGoogle ScholarCrossref
12.
McFadden EP, Stabile E, Regar E,  et al.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.  Lancet. 2004;364(9444):1519-152115500897PubMedGoogle ScholarCrossref
13.
Pfisterer M, Brunner-LaRocca HP, Buser PT,  et al.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents.  J Am Coll Cardiol. 2006;48(12):2584-259117174201PubMedGoogle ScholarCrossref
14.
Stone GW, Moses JW, Ellis SG,  et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.  N Engl J Med. 2007;356(10):998-100817296824PubMedGoogle ScholarCrossref
15.
Favarato ME, Hueb W, Boden WE,  et al.  Quality of life in patients with symptomatic multivessel coronary artery disease: a comparative post hoc analyses of medical, angioplasty or surgical strategies-MASS II trial.  Int J Cardiol. 2007;116(3):364-37016876891PubMedGoogle ScholarCrossref
16.
Pfisterer M, Buser P, Osswald S,  et al.  Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial.  JAMA. 2003;289(9):1117-112312622581PubMedGoogle ScholarCrossref
17.
Pocock SJ, Henderson RA, Clayton T, Lyman GH, Chamberlain DA. Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial: Randomized Intervention Treatment of Angina.  J Am Coll Cardiol. 2000;35(4):907-91410732887PubMedGoogle ScholarCrossref
18.
Strauss WE, Fortin T, Hartigan P, Folland ED, Parisi AF.Veterans Affairs Study of Angioplasty Compared to Medical Therapy Investigators.  A comparison of quality of life scores in patients with angina pectoris after angioplasty compared with after medical therapy: outcomes of a randomized clinical trial.  Circulation. 1995;92(7):1710-17197671352PubMedGoogle ScholarCrossref
19.
Spertus JA, Salisbury AC, Jones PG, Conaway DG, Thompson RC. Predictors of quality-of-life benefit after percutaneous coronary intervention.  Circulation. 2004;110(25):3789-379415596563PubMedGoogle ScholarCrossref
20.
Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography.  Circulation. 2003;107(23):2900-290712771008PubMedGoogle ScholarCrossref
21.
Shaw LJ, Berman DS, Maron DJ,  et al.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.  Circulation. 2008;117(10):1283-129118268144PubMedGoogle ScholarCrossref
22.
Lin GA, Dudley RA, Redberg RF. Cardiologists' use of percutaneous coronary interventions for stable coronary artery disease.  Arch Intern Med. 2007;167(15):1604-160917698682PubMedGoogle ScholarCrossref
23.
Shaw LJ, Berman DS, Blumenthal RS,  et al.  Clinical imaging for prevention: directed strategies for improved detection of presymptomatic patients with undetected atherosclerosis, part I: clinical imaging for prevention.  J Nucl Cardiol. 2008;15(1):e6-e1918242470PubMedGoogle ScholarCrossref
24.
Zellweger MJ, Weinbacher M, Zutter AW,  et al.  Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting.  J Am Coll Cardiol. 2003;42(1):33-4012849656PubMedGoogle ScholarCrossref
25.
Smith SC Jr, Feldman TE, Hirshfeld JW Jr,  et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).  Circulation. 2006;113(7):e166-e28616490830PubMedGoogle ScholarCrossref
26.
Anderson HV, Shaw RE, Brindis RG,  et al.  Relationship between procedure indications and outcomes of percutaneous coronary interventions by American College of Cardiology/American Heart Association Task Force Guidelines.  Circulation. 2005;112(18):2786-279116267252PubMedGoogle ScholarCrossref
27.
Shaw LJ, Hachamovitch R, Berman DS,  et al; Economics of Noninvasive Diagnosis (END) Multicenter Study Group.  The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheterization ischemia.  J Am Coll Cardiol. 1999;33(3):661-66910080466PubMedGoogle ScholarCrossref
28.
Topol EJ, Ellis SG, Cosgrove DM,  et al.  Analysis of coronary angioplasty practice in the United States with an insurance-claims data base.  Circulation. 1993;87(5):1489-14978141866PubMedGoogle ScholarCrossref
29.
Wennberg JE, ed, Cooper MM, edThe Dartmouth Atlas of Health Care. Chicago, IL: American Hospital Association; 1996
30.
Lucas FL, Siewers AE, DeLorenzo MA, Wennberg DE. Differences in cardiac stress testing by sex and race among Medicare beneficiaries.  Am Heart J. 2007;154(3):502-50917719298PubMedGoogle ScholarCrossref
31.
Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives.  J Clin Epidemiol. 1993;46(10):1075-10798410092PubMedGoogle ScholarCrossref
32.
Larsen K, Petersen JH, Budtz-Jorgensen E, Endahl L. Interpreting parameters in the logistic regression model with random effects.  Biometrics. 2000;56(3):909-91410985236PubMedGoogle ScholarCrossref
33.
Wennberg DE, Kellett MA, Dickens JD, Malenka DJ, Keilson LM, Keller RB. The association between local diagnostic testing intensity and invasive cardiac procedures.  JAMA. 1996;275(15):1161-11648609682PubMedGoogle ScholarCrossref
34.
Wennberg D, Dickens J Jr, Soule D,  et al.  The relationship between the supply of cardiac catheterization laboratories, cardiologists and the use of invasive cardiac procedures in northern New England.  J Health Serv Res Policy. 1997;2(2):75-8010180368PubMedGoogle Scholar
35.
Lucas FL, Wennberg DE, Malenka DJ. Variation in the use of echocardiography.  Eff Clin Pract. 1999;2(2):71-7510538479PubMedGoogle Scholar
36.
Hannan EL, Wu C, Chassin MR. Differences in per capita rates of revascularization and in choice of revascularization procedure for eleven states.  BMC Health Serv Res. 2006;6:35-4316542441PubMedGoogle ScholarCrossref
37.
Shaw LJ, Miller DD, Romeis JC, Kargl D, Younis LT, Chaitman BR. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease.  Ann Intern Med. 1994;120(7):559-5668116993PubMedGoogle ScholarCrossref
38.
Tobin JN, Wassertheil-Smoller S, Wexler JP,  et al.  Sex bias in considering coronary bypass surgery.  Ann Intern Med. 1987;107(1):19-253496029PubMedGoogle ScholarCrossref
39.
Hlatky MA, Pryor DB, Harrell FE Jr, Califf RM, Mark DB, Rosati RA. Factors affecting sensitivity and specificity of exercise electrocardiography: multivariable analysis.  Am J Med. 1984;77(1):64-716741986PubMedGoogle ScholarCrossref
40.
Kwok Y, Kim C, Grady D, Segal M, Redberg R. Meta-analysis of exercise testing to detect coronary artery disease in women.  Am J Cardiol. 1999;83(5):660-66610080415PubMedGoogle ScholarCrossref
41.
Lee CH, Tan M, Yan AT,  et al.  Use of cardiac catheterization for non–ST-segment elevation acute coronary syndromes according to initial risk: reasons why physicians choose not to refer their patients.  Arch Intern Med. 2008;168(3):291-29618268170PubMedGoogle ScholarCrossref
42.
Poses RM, Krueger JI, Sloman S, Elstein AS. Physicians' judgments of survival after medical management and mortality risk reduction due to revascularization procedures for patients with coronary artery disease.  Chest. 2002;122(1):122-13312114347PubMedGoogle ScholarCrossref
43.
Wennberg DE, Dickens JD, Biener L, Fowler FJ, Soule DN, Keller RB. Do physicians do what they say? the inclination to test and its association with coronary angiography rates.  J Gen Intern Med. 1997;12(3):172-1769100142PubMedGoogle Scholar
44.
Cabana MD, Rand CS, Powe NR,  et al.  Why don't physicians follow clinical practice guidelines? a framework for improvement.  JAMA. 1999;282(15):1458-146510535437PubMedGoogle ScholarCrossref
45.
McGlynn EA, Asch SM, Adams J,  et al.  The quality of health care delivered to adults in the United States.  N Engl J Med. 2003;348(26):2635-264512826639PubMedGoogle ScholarCrossref
46.
Peterson ED, Roe MT, Mulgund J,  et al.  Association between hospital process performance and outcomes among patients with acute coronary syndromes.  JAMA. 2006;295(16):1912-192016639050PubMedGoogle ScholarCrossref
47.
Rogers AM, Ramanath VS, Grzybowski M,  et al.  The association between guideline-based treatment instructions at the point of discharge and lower 1-year mortality in Medicare patients after acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) initiative in Michigan.  Am Heart J. 2007;154(3):461-46917719291PubMedGoogle ScholarCrossref
48.
Campione JR, Sleath B, Biddle AK, Weinberger M. The influence of physicians' guideline compliance on patients' statin adherence: a retrospective cohort study.  Am J Geriatr Pharmacother. 2005;3(4):229-23916503318PubMedGoogle ScholarCrossref
49.
Nallamothu BK, Rogers MAM, Chernew ME, Krumholz HM, Eagle KA, Birkmeyer JD. Opening of specialty cardiac hospitals and use of coronary revascularization in Medicare beneficiaries.  JAMA. 2007;297(9):962-96817341710PubMedGoogle ScholarCrossref
50.
Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending, part 2: health outcomes and satisfaction with care.  Ann Intern Med. 2003;138(4):288-29812585826PubMedGoogle ScholarCrossref
Original Contribution
October 15, 2008

Frequency of Stress Testing to Document Ischemia Prior to Elective Percutaneous Coronary Intervention

Author Affiliations

Author Affiliations: Divisions of General Internal Medicine (Dr Lin), Epidemiology and Biostatistics (Dr Vittinghoff), and Cardiology (Dr Redberg), and Institute for Health Policy Studies (Dr Dudley), University of California, San Francisco; Center for Outcomes Research and Evaluation, Maine Medical Center, Portland (Dr Lucas); and Division of Cardiology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire (Dr Malenka).

JAMA. 2008;300(15):1765-1773. doi:10.1001/jama.300.15.1765
Abstract

Context Guidelines call for documenting ischemia in patients with stable coronary artery disease prior to elective percutaneous coronary intervention (PCI).

Objective To determine the frequency and predictors of stress testing prior to elective PCI in a Medicare population.

Design, Setting, and Patients Retrospective, observational cohort study using claims data from a 20% random sample of 2004 Medicare fee-for-service beneficiaries aged 65 years or older who had an elective PCI (N = 23 887).

Main Outcome Measures Percentage of patients who underwent stress testing within 90 days prior to elective PCI; variation in stress testing prior to PCI across 306 hospital referral regions; patient, physician, and hospital characteristics that predicted the appropriate use of stress testing prior to elective PCI.

Results In the United States, 44.5% (n = 10 629) of patients underwent stress testing within the 90 days prior to elective PCI. There was wide regional variation among the hospital referral regions with stress test rates ranging from 22.1% to 70.6% (national mean, 44.5%; interquartile range, 39.0%-50.9%). Female sex (adjusted odds ratio [AOR], 0.91; 95% confidence interval [CI], 0.86-0.97), age of 85 years or older (AOR, 0.83; 95% CI, 0.72-0.95), a history of congestive heart failure (AOR, 0.85; 95% CI, 0.79-0.92), and prior cardiac catheterization (AOR, 0.45; 95% CI, 0.38-0.54) were associated with a decreased likelihood of prior stress testing. A history of chest pain (AOR, 1.28; 95% CI, 1.09-1.54) and black race (AOR, 1.26; 95% CI, 1.09-1.46) increased the likelihood of stress testing prior to PCI. Patients treated by physicians performing 150 or more PCIs per year were less likely to have stress testing prior to PCI (AOR, 0.84; 95% CI, 0.77-0.93). No hospital characteristics were associated with receipt of stress testing.

Conclusion The majority of Medicare patients with stable coronary artery disease do not have documentation of ischemia by noninvasive testing prior to elective PCI.

In the United States, percutaneous coronary intervention (PCI) has become a common treatment strategy for patients with stable coronary artery disease (CAD) and such patients now account for the majority of PCIs performed.1,2 However, multiple studies have established that some important outcomes for patients with stable CAD (death and risk of future myocardial infarction) do not differ between patients treated with PCI plus optimal medical therapy and patients treated with optimal medical therapy alone.3-10 The addition of PCI does offer quicker relief of angina than medical therapy alone but also carries an increased risk of repeat revascularization, late-stent thrombosis, and a decreased quality of life if performed in patients with minimal symptoms.3,11-19

There also is evidence that PCI reduces ischemia to a greater extent than medical therapy.20,21 Reduction of ischemia has been suggested by some cardiologists as a rationale for performing PCI even in asymptomatic patients.22-24 Given these considerations, guidelines for PCI published jointly by the American College of Cardiology, the American Heart Association, and the Society for Cardiovascular Angiography and Intervention state that for patients with stable angina, any vessels to be dilated must be shown to be “associated with a moderate to severe degree of ischemia on noninvasive testing.”25 Previous studies have shown that patients who receive PCI in accordance with these guidelines have better outcomes.26 In addition, stress testing prior to cardiac catheterization and angioplasty has been associated with lower overall diagnostic costs, shorter hospital stays, and lower rates of revascularization, without adverse effects on cardiac death or myocardial infarction.27,28

With the increasingly widespread use of PCI in patients with stable CAD, it is important that the procedure is being performed in patients for whom there is reasonable expectation of benefit (ie, patients with documented ischemia and/or symptoms). However, the frequency with which ischemia is documented prior to PCI is unknown in the current era of PCI with stenting and this creates uncertainty about whether PCI is being performed in patients in whom benefits outweigh risks. Because professional guidelines call for objective documentation of ischemia prior to elective PCI, we hypothesized that the majority of patients undergoing elective PCI would have had a stress test because this is the most common method of documenting ischemia. Therefore, we undertook a study of Medicare beneficiaries throughout the United States undergoing elective PCI to determine the frequency with which stress testing was performed prior to PCI and to examine the predictors of receipt of stress testing prior to PCI.

Methods

The study was approved by the institutional review boards at the University of California, San Francisco, and Maine Medical Center.

Data Sources

To identify patients undergoing elective PCI, data on the use of noninvasive stress testing prior to PCI were obtained for a 20% random sample of Medicare beneficiaries. Selection was based on the last digit of 0 or 5 in a unique patient identifier assigned by Medicare and recorded in the Centers for Medicare & Medicaid Services' Medicare Provider Analysis and Review (MEDPAR), physician and supplier, and denominator files between January 1, 2003, and December 31, 2004. The MEDPAR files (Part A) and physician and supplier files (Part B) contain data on services provided to Medicare fee-for-service beneficiaries, including hospitalizations, physician claims, and outpatient services. The files contain unique identifiers for individual patients, physicians, and hospitals; date and place of service; and diagnoses and procedures as defined by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes and the physicians' Current Procedural Terminology (CPT) codes. The denominator files have enrollment and demographic data for every Medicare beneficiary for the entire year.

To examine possible relationships between use of prior noninvasive testing and characteristics of physicians, the unique physician identifying number from each claim was matched to the American Medical Association's Physician Masterfile. This database contains information on all physicians in the United States, including age, sex, year of graduation, geographic location, specialty, and board certification.

To examine possible relationships between the use of prior noninvasive testing and characteristics of hospitals, the unique hospital identification number from each claim was matched to the American Hospital Association's annual survey database from 2004. The survey contains information on hospital organizational structure, facilities and services, geographic location, accreditation, and teaching status.

Patient Population

Using Part B claims from 2004, the CPT codes for PCI (92980-92982, 92984, 92995-92996) were used to identify patients undergoing PCI. The population was then limited to patients who had a denominator record, were eligible because of age, were eligible for both Part A and Part B, had at least 12 months of eligibility prior to the index PCI, and were enrolled in the Medicare fee-for-service program. The first PCI was selected per patient (index PCI). We then linked MEDPAR and Part B data to create a file containing patients who had a PCI in 2004 and had a complete year of claims available prior to the index PCI.

Patients were excluded if they had a primary diagnosis of acute myocardial infarction (ICD-9-CM codes 410.XX) or unstable angina (ICD-9-CM codes 411.1, 411.81, 411.89). Patients who had PCI, coronary artery bypass graft surgery, valve surgery, acute myocardial infarction, or unstable angina within 1 year prior to the index PCI also were excluded. We further excluded patients if they were admitted from an emergency department, transferred from another institution, or had emergency procedures.

Each included patient was assigned to 1 of 306 hospital referral regions based on referral patterns for tertiary care and the patient's ZIP code of residence, and as defined in the Dartmouth Atlas of Health Care.29

Definition of Stress Test

The CPT codes were used for stress echocardiography (93350), exercise treadmill or pharmacological stress test (93015, 93016-93018), and myocardial nuclear imaging (78460-78461, 78464-78466, 78468-78469, 78472-78473, 78478, 78480-78481, 78483, 78491-78492, 78494, 78496) to identify stress tests for each patient. For imaging stress tests, patients must have had both a stress component and an associated imaging component within a 1-day window.

Analyses

Statistical analyses were performed using SAS version 8 (SAS Institute Inc, Cary, North Carolina), STATA version 9.0 (StataCorp, College Station, Texas), and MlwiN (Center for Multilevel Modeling, Bristol, England) statistical software. We calculated the percentage of all patients who underwent a stress test in the 90 days prior to PCI, stratified by hospital referral regions.

Hospital referral regions with less than 25 PCIs were excluded for the purpose of calculating regional (ie, specific to the hospital referral region) stress testing rates because there were too few procedures to accurately determine those rates. Exclusion of hospital referral regions was done for the analysis of geographic variation only; all patients and hospital referral regions were included for the main analyses.

The relationship between patient, physician, and hospital characteristics and the probability of receiving stress testing prior to PCI was then examined. Patient characteristics examined included age, sex, race, and comorbidities. Race was included as a predictor variable because previous studies have documented racial differences in the receipt of stress testing.30 The ICD-9-CM codes were used to identify diagnoses typically included in the Charlson comorbidity score, including prior myocardial infarction, peripheral vascular disease, chronic obstructive pulmonary disease, renal disease, severe diabetes mellitus, severe liver disease, congestive heart failure, rheumatic disease, cerebrovascular disease, peptic ulcer disease, metastatic cancer, dementia, and AIDS.31 The ICD-9-CM codes also were used to identify diagnoses of angina, chest pain, CAD, hyperlipidemia, hypertension, and prior cardiac catheterization for each patient. The comorbidities and diagnoses to be included in the final model were determined a priori based on their clinical relevance to the likelihood of stress testing.

For physician characteristics, we analyzed physician age, sex, specialty (cardiology, interventional cardiology, internal medicine, or other), and board certification status; years since graduation was omitted due to its colinearity with physician age. The volume of PCIs performed by each physician, multiplied by a factor of 5, also was calculated to estimate total Medicare volume for that physician in 2004, and physicians were categorized into volume quartiles (≤59, 60-94, 95-149, ≥150).

For hospital characteristics, we analyzed variables that may affect rates of stress testing, including hospital association with an outpatient surgery center, having single photon emission computed tomography (CT), electron beam CT, multislice spiral CT, or cardiac catheterization facilities, and having interventional cardiology or adult cardiac surgery services. Hospital teaching status was defined as having been accredited by either the Council of Teaching Hospitals or the Accreditation Council for Graduate Medical Education. Hospital volume of PCI performed in 2004, multiplied by a factor of 5, also was calculated to estimate total Medicare volume for that hospital, and hospitals were categorized into volume quartiles (<285, 285-485, 486-849, ≥850). We also examined whether there was a correlation between PCI volume and likelihood of stress testing within hospital referral regions by calculating a Pearson correlation coefficient.

To determine independent predictors of receiving stress testing, a hierarchical logistic-normal regression model was used with nested random effects to adjust for the effects of hospital referral region, hospital, and physician. The model was estimated using penalized quasi likelihood, as implemented in MlwiN software, and yielded adjusted odds ratios (AORs) with 95% confidence intervals (CIs) relating to the likelihood of stress test receipt. The variance of the random effects was tested for statistical significance, and the influence of the underlying system-level factors was summarized by the median relative difference in the odds of stress testing between 2 randomly selected hospital referral regions, hospitals, or physicians; under the normality assumption, this summary statistic is a simple function of the estimated variance of the random effect.32 The minimum OR detectable with 80% power in a 2-sided test with an α level of .05 was 1.48 for a rare binary covariate of prevalence 1% and reached a minimum of 1.08 for an exposure of prevalence 50%. Interactions between patient age, sex, and race were assessed, as well as interactions between physician volume and hospital volume.

Because our Medicare cohort included only patients aged 65 years or older, we analyzed the rate of stress testing prior to elective PCI in 1630 commercially insured patients who underwent PCI in a 1-year period from October 1, 2005, through September 30, 2006, as a comparison group. The data were drawn from an analytical database fed by the claims and administrative data systems, and included all enrollment information, all claims (from both preferred provider organizations and health maintenance organizations), and all submitted encounters (from health maintenance organizations). We used the same inclusion and exclusion criteria and the same algorithm to determine stress testing rates.

Results

A total of 87 343 patients undergoing PCI in 2004 were identified from 107 162 Medicare line-item claims. Of these, 23 887 met the eligibility criteria and became the study cohort (Figure 1). In the United States, 44.5% (n = 10 629) of patients underwent stress testing within the 90 days prior to elective PCI. Patients undergoing elective PCI were mostly male (60.3%) and mostly white (92.7%). In unadjusted analyses, older patients had lower overall rates of prior stress testing, as did patients with angina, prior CAD, prior cardiac catheterization, chronic obstructive pulmonary disease, and congestive heart failure (Table 1). Patients of physicians who performed a higher volume of PCI had slightly lower rates of stress testing (Table 2). Patients who had their PCI performed at hospitals that were associated with a freestanding outpatient surgery center that owned single photon emission CT or multislice CT scanners had slightly higher rates of stress testing (Table 2).

Figure 2 shows significant geographic variation in the rate of stress testing by hospital referral region, with rates ranging from a low of 22.1% to a high of 70.6% (interquartile range, 39.0%-50.9%). The rate of stress testing did not correlate with the volume of PCI performed in the hospital referral region (Pearson correlation coefficient, −0.043); ie, a hospital referral region with a high volume of PCI did not necessarily have a high percentage of stress testing and vice versa.

For the multivariate model, patients with missing predictor data were excluded so that a total of 20 399 patients were included in a hierarchical logistic model to determine the predictors of undergoing stress testing prior to PCI. Patients who had a cardiac catheterization previously were least likely to undergo stress testing prior to elective PCI (AOR, 0.45; 95% CI, 0.38-0.54). Female sex (AOR, 0.91; 95% CI, 0.86-0.97), age of 85 years or older (AOR, 0.83; 95% CI, 0.72-0.95), and having comorbidities such as rheumatic disease (AOR, 0.80; 95% CI, 0.69-0.94), chronic obstructive pulmonary disease (AOR, 0.83; 95% CI, 0.78-0.89), congestive heart failure (AOR, 0.85; 95% CI, 0.79-0.92), and CAD (AOR, 0.90; 95% CI, 0.81-1.00) also were independent negative predictors of stress testing prior to PCI (Figure 3). Conversely, patient characteristics associated with a higher likelihood of a stress test prior to PCI were being black (AOR, 1.26; 95% CI, 1.09-1.46) and having a diagnosis of chest pain (AOR, 1.28; 95% CI, 1.09-1.54).

Physician age was a significant predictor of the likelihood of receiving a stress test. Patients of physicians aged 50 to 69 years were less likely to receive a stress test prior to PCI than those of physicians younger than 40 years old, while patients of the oldest physicians (age ≥70 years) were more likely to undergo stress testing prior to PCI than those of the younger physicians (age <40 years) (Figure 3). In addition, there was an inverse relationship between physician PCI volume and receipt of stress test. Patients of physicians who performed a low (60-94), medium (95-149), and high (≥150) volume of PCIs were less likely to undergo stress testing within 90 days prior to PCI (AOR, 0.91 [95% CI, 0.84-0.99]; 0.88 [95% CI, 0.81-0.96], and 0.84 [95% CI, 0.77-0.93], respectively) compared with patients of physicians who performed less than 60 PCIs. No hospital factors were independent predictors of stress test receipt, and no interactions having both statistical and clinical significance were found.

The influence of system-level factors (ie, physician, hospital, and hospital referral region) on receiving a stress test prior to PCI was assessed. After controlling for all other factors included in the model, the median relative difference between physicians in odds of stress testing (ie, the likelihood patients from different physicians underwent stress testing prior to PCI) was 40%. Similarly, the median difference in the odds of stress testing between 2 hospital referral regions was 22% and between hospitals was 18%. Thus, although many of system-level factors were not significant predictors by themselves, collectively these factors played roles as large as or larger than patient characteristics in predicting whether stress testing prior to PCI was performed.

Finally, the rate of stress testing prior to elective PCI was examined in a comparison cohort of commercially insured patients and it was found that 34.4% of patients underwent stress testing prior to elective PCI during a 1-year period.

Comment

We found that less than half of Medicare patients who underwent elective PCI had a stress test in the 90 days prior to the procedure, and that this proportion varied widely by region and with physician characteristics (even after adjusting for patient factors that may drive use of PCI). Variation in use driven by nonclinical factors begs the question of what proportion of PCI in our sample is actually appropriate. In fact, our data may overestimate the overall rate of stress testing prior to elective PCI. We and Topol et al28 found even lower rates (34.4% and 29%, respectively) in commercially insured populations. Without documentation of ischemia, PCIs may have been performed in patients who would not have benefited from the procedure.

We found significant geographic variation in stress testing, providing another example in which where one lives determines the likelihood and intensity of testing and intervention.33-35 Because stress testing is widely available, it is not clear why such variation should exist, and the likelihood of stress testing does not appear to be related to the volume of PCI performed in a region. Geographic variation in practice patterns has been documented for many procedures, including PCI,29,36 and our data further support that local practice patterns may supersede clinical guidelines and evidence from clinical trials in the decision-making process for patients with stable CAD. Such variation may result in overuse or underuse of PCI in certain populations, leading to inefficient and potentially ineffective care.

We found that patient characteristics affected the rate of stress testing independently of geographic effects. Patients having had prior cardiac catheterization were the least likely to undergo stress testing prior to PCI. Older patients and those with comorbidities also were less likely to undergo stress testing prior to PCI. Although these factors do increase the probability that obstructive CAD is present, evidence of ischemia (not just visualization of anatomy) is crucial in determining if the use of PCI is appropriate.

Women were less likely than men to undergo stress testing prior to PCI, which is consistent with previous studies.30 This may be due in part to the fact that women are more likely to have symptoms that are atypical or are attributed to noncardiac diseases, and also may reflect the lower sensitivity and specificity of stress testing in women, leading physicians to rely less on stress testing to diagnose cardiac disease in women.37-40 On the other hand, we found that patients with a diagnosis of chest pain and blacks were more likely to undergo stress testing prior to PCI. This is in contrast to an earlier study documenting lower population rates of stress testing in blacks compared with whites.30 However, regardless of the direction of the association, these findings support the view that sex and race influence the decision to refer for stress testing and PCI. Referral for testing on the basis of perceived risk, rather than objective evidence of ischemia, also has been demonstrated in referral for cardiac catheterization in patients with non–ST-segment elevation myocardial infarction.41

We found that physician characteristics such as younger age and higher volume of PCI performed predicted lower rates of stress testing prior to PCI. There also was substantial unexplained variation among physicians. This suggests that physician decision making regarding PCI was influenced less by presence of ischemia, as PCI guidelines suggest, and more by physicians' own biases and community practice patterns.22,42,43 While many of the physicians in our sample may have had the patient referred to them specifically for a PCI and may not have done the initial evaluation of the patient, our data would have captured a stress test ordered by any physician. In addition, the variation in the rate of stress testing by hospital referral region did not correlate with the hospital referral region volume of PCI, further suggesting that there may not have been systematic adherence to guidelines. Physician adherence to guidelines has been documented to be suboptimal in many situations,44,45 even though adherence to guidelines has been demonstrated to improve quality of care, particularly in patients with CAD.46-48 Thus, the geographic variation and low overall rates of stress testing could be partially ameliorated by promoting better adherence to clinical practice guidelines.

We found that the influence of system-level factors (ie, physician, hospital, and geographic characteristics) on stress testing is as strong as or stronger than the most important patient-level effects assessed, even if the specific characteristics measured at the physician or hospital level were not significant. In fact, the effect of choice of physician (median relative OR, 1.40) was greater than any single patient characteristic, underscoring the magnitude of physician influence on the rate of stress testing prior to PCI. The fact that all system-level effects were significant indicates that the rate of stress testing may be affected by factors such as the availability of catheterization laboratories or the density of specialists in a region.49 The specific system-level characteristics that are most influential need to be better defined to understand how to design health system–level interventions to address the low rate of stress testing in Medicare patients.

Our study has several limitations. Our analysis is based on administrative data in Medicare patients, and lacks clinical data not documented by the clinicians or coded in the billing process (eg, <5% of patients had angina or chest pain coded). Also, as with all retrospective, observational studies using administrative databases, our results are limited by uncertainties in patient selection and unmeasured confounding variables that may affect a patient's likelihood of undergoing stress testing. Although we would not expect that 100% of elective PCIs would be preceded by stress testing, there were regions with stress testing rates of 70%, suggesting that the overall stress testing prior to PCI rate of 44.5% may be too low. Because our cohort only included Medicare patients, our results may not necessarily be generalizable to younger patients or those with a different insurance status.

We chose a 90-day time window to assess the rate of stress testing prior to PCI, which may miss patients who undergo PCI only after optimal medical therapy alone fails to improve symptoms. However, extending our surveillance prior to PCI to 180 days did not substantially increase the rate of stress testing prior to PCI (49.1% at 180 days). With previous history limited to 1 year prior to the procedure, we may not have fully ascertained the number of patients with prior PCI, coronary artery bypass graft surgery, or diagnosis of CAD. In addition, we could not assess the use of newer noninvasive imaging modalities such as electron beam CT, multislice CT angiography, or cardiac magnetic resonance angiography because Medicare did not cover those tests in 2004 for the diagnosis of cardiac disease. These tests visualize atherosclerosis and thus may lead to cardiac catheterization and subsequent PCI based on anatomical data, without documentation of ischemia by stress testing. Further study needs to be done to establish what role these tests may play in the use of PCI.

Percutaneous coronary intervention is an important treatment option for stable CAD, and its use has increased by more than 300% over the past decade.1 Guidelines for PCI call for documenting ischemia prior to PCI in the vast majority of patients with stable CAD; however, our data suggest that this is not being done consistently. Assessing whether PCI is being performed in appropriately selected patients is crucial to providing high-quality, patient-centered medical care in light of evidence that patients in regions providing high-intensity care do not have better (and sometimes have worse) outcomes than those in regions providing low-intensity care.50

In addition, because Medicare spends $10 000 to $15 000 per PCI and PCI has accounted for at least 10% of the increase in Medicare spending since the mid-1990s, it is important to document that patients are receiving PCI for appropriate indications to ensure the optimal use of Medicare resources. Our findings highlight an opportunity for improvement in the care of patients with stable CAD and suggest that current proposals to restructure Medicare payment to reward hospitals and physicians who adhere to guidelines would improve the safety and delivery of health care to Medicare beneficiaries while decreasing Medicare expenditures on costly and inappropriate procedures.

Back to top
Article Information

Corresponding Author: Rita F. Redberg, MD, MSc, 505 Parnassus Ave, Ste M-1180, School of Medicine, Division of Cardiology, San Francisco, CA 94143 (redberg@medicine.ucsf.edu).

Author Contributions: Dr Lin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Lin, Dudley, Lucas, Malenka, Redberg.

Acquisition of data: Lin, Dudley, Lucas.

Analysis and interpretation of data: Lin, Dudley, Lucas, Malenka, Vittinghoff, Redberg.

Drafting of the manuscript: Lin, Dudley, Malenka, Vittinghoff.

Critical revision of the manuscript for important intellectual content: Lin, Dudley, Lucas, Malenka, Redberg.

Statistical analysis: Lin, Dudley, Lucas, Malenka, Vittinghoff.

Obtained funding: Dudley, Redberg.

Administrative, technical, or material support: Dudley, Lucas, Malenka.

Study supervision: Dudley, Lucas, Malenka, Redberg.

Financial Disclosures: None reported.

Funding/Support: This study was funded by the Blue Shield of California Foundation. A portion of Dr Dudley's work was supported by an Investigator Award in Health Policy from the Robert Wood Johnson Foundation.

Role of the Sponsor: The Blue Shield of California Foundation and the Robert Wood Johnson Foundation had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.

References
1.
Rosamond W, Flegal K, Friday G,  et al.  Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.  Circulation. 2007;115(5):e69-e17117194875PubMedGoogle ScholarCrossref
2.
Lucas FL, DeLorenzo MA, Siewers AE, Wennberg DE. Temporal trends in the utilization of diagnostic testing and treatments for cardiovascular disease in the United States, 1993-2001.  Circulation. 2006;113(3):374-37916432068PubMedGoogle ScholarCrossref
3.
Boden WE, O'Rourke RA, Teo KK,  et al.  Optimal medical therapy with or without PCI for stable coronary disease.  N Engl J Med. 2007;356(15):1503-151617387127PubMedGoogle ScholarCrossref
4.
Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: a meta-analysis of randomised controlled trials.  BMJ. 2000;321(7253):73-7710884254PubMedGoogle ScholarCrossref
5.
Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus medical therapy in nonacute coronary artery disease.  Circulation. 2005;111(22):2906-291215927966PubMedGoogle ScholarCrossref
6.
Folland ED, Hartigan PM, Parisi AF.Veterans Affairs ACME Investigators.  Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial.  J Am Coll Cardiol. 1997;29(7):1505-15119180111PubMedGoogle ScholarCrossref
7.
Pitt B, Waters D, Brown WV,  et al; Atorvastatin versus Revascularization Treatment Investigators.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.  N Engl J Med. 1999;341(2):70-7610395630PubMedGoogle ScholarCrossref
8.
Henderson RA, Pocock SJ, Clayton TC,  et al.  Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy.  J Am Coll Cardiol. 2003;42(7):1161-117014522473PubMedGoogle ScholarCrossref
9.
Hueb W, Lopes NH, Gersh BJ,  et al.  Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.  Circulation. 2007;115(9):1082-108917339566PubMedGoogle ScholarCrossref
10.
Hueb W, Soares PR, Gersh BJ,  et al.  The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results.  J Am Coll Cardiol. 2004;43(10):1743-175115145093PubMedGoogle ScholarCrossref
11.
Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.  N Engl J Med. 2007;356(10):1009-101917296822PubMedGoogle ScholarCrossref
12.
McFadden EP, Stabile E, Regar E,  et al.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.  Lancet. 2004;364(9444):1519-152115500897PubMedGoogle ScholarCrossref
13.
Pfisterer M, Brunner-LaRocca HP, Buser PT,  et al.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents.  J Am Coll Cardiol. 2006;48(12):2584-259117174201PubMedGoogle ScholarCrossref
14.
Stone GW, Moses JW, Ellis SG,  et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.  N Engl J Med. 2007;356(10):998-100817296824PubMedGoogle ScholarCrossref
15.
Favarato ME, Hueb W, Boden WE,  et al.  Quality of life in patients with symptomatic multivessel coronary artery disease: a comparative post hoc analyses of medical, angioplasty or surgical strategies-MASS II trial.  Int J Cardiol. 2007;116(3):364-37016876891PubMedGoogle ScholarCrossref
16.
Pfisterer M, Buser P, Osswald S,  et al.  Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial.  JAMA. 2003;289(9):1117-112312622581PubMedGoogle ScholarCrossref
17.
Pocock SJ, Henderson RA, Clayton T, Lyman GH, Chamberlain DA. Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial: Randomized Intervention Treatment of Angina.  J Am Coll Cardiol. 2000;35(4):907-91410732887PubMedGoogle ScholarCrossref
18.
Strauss WE, Fortin T, Hartigan P, Folland ED, Parisi AF.Veterans Affairs Study of Angioplasty Compared to Medical Therapy Investigators.  A comparison of quality of life scores in patients with angina pectoris after angioplasty compared with after medical therapy: outcomes of a randomized clinical trial.  Circulation. 1995;92(7):1710-17197671352PubMedGoogle ScholarCrossref
19.
Spertus JA, Salisbury AC, Jones PG, Conaway DG, Thompson RC. Predictors of quality-of-life benefit after percutaneous coronary intervention.  Circulation. 2004;110(25):3789-379415596563PubMedGoogle ScholarCrossref
20.
Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography.  Circulation. 2003;107(23):2900-290712771008PubMedGoogle ScholarCrossref
21.
Shaw LJ, Berman DS, Maron DJ,  et al.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.  Circulation. 2008;117(10):1283-129118268144PubMedGoogle ScholarCrossref
22.
Lin GA, Dudley RA, Redberg RF. Cardiologists' use of percutaneous coronary interventions for stable coronary artery disease.  Arch Intern Med. 2007;167(15):1604-160917698682PubMedGoogle ScholarCrossref
23.
Shaw LJ, Berman DS, Blumenthal RS,  et al.  Clinical imaging for prevention: directed strategies for improved detection of presymptomatic patients with undetected atherosclerosis, part I: clinical imaging for prevention.  J Nucl Cardiol. 2008;15(1):e6-e1918242470PubMedGoogle ScholarCrossref
24.
Zellweger MJ, Weinbacher M, Zutter AW,  et al.  Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting.  J Am Coll Cardiol. 2003;42(1):33-4012849656PubMedGoogle ScholarCrossref
25.
Smith SC Jr, Feldman TE, Hirshfeld JW Jr,  et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).  Circulation. 2006;113(7):e166-e28616490830PubMedGoogle ScholarCrossref
26.
Anderson HV, Shaw RE, Brindis RG,  et al.  Relationship between procedure indications and outcomes of percutaneous coronary interventions by American College of Cardiology/American Heart Association Task Force Guidelines.  Circulation. 2005;112(18):2786-279116267252PubMedGoogle ScholarCrossref
27.
Shaw LJ, Hachamovitch R, Berman DS,  et al; Economics of Noninvasive Diagnosis (END) Multicenter Study Group.  The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheterization ischemia.  J Am Coll Cardiol. 1999;33(3):661-66910080466PubMedGoogle ScholarCrossref
28.
Topol EJ, Ellis SG, Cosgrove DM,  et al.  Analysis of coronary angioplasty practice in the United States with an insurance-claims data base.  Circulation. 1993;87(5):1489-14978141866PubMedGoogle ScholarCrossref
29.
Wennberg JE, ed, Cooper MM, edThe Dartmouth Atlas of Health Care. Chicago, IL: American Hospital Association; 1996
30.
Lucas FL, Siewers AE, DeLorenzo MA, Wennberg DE. Differences in cardiac stress testing by sex and race among Medicare beneficiaries.  Am Heart J. 2007;154(3):502-50917719298PubMedGoogle ScholarCrossref
31.
Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives.  J Clin Epidemiol. 1993;46(10):1075-10798410092PubMedGoogle ScholarCrossref
32.
Larsen K, Petersen JH, Budtz-Jorgensen E, Endahl L. Interpreting parameters in the logistic regression model with random effects.  Biometrics. 2000;56(3):909-91410985236PubMedGoogle ScholarCrossref
33.
Wennberg DE, Kellett MA, Dickens JD, Malenka DJ, Keilson LM, Keller RB. The association between local diagnostic testing intensity and invasive cardiac procedures.  JAMA. 1996;275(15):1161-11648609682PubMedGoogle ScholarCrossref
34.
Wennberg D, Dickens J Jr, Soule D,  et al.  The relationship between the supply of cardiac catheterization laboratories, cardiologists and the use of invasive cardiac procedures in northern New England.  J Health Serv Res Policy. 1997;2(2):75-8010180368PubMedGoogle Scholar
35.
Lucas FL, Wennberg DE, Malenka DJ. Variation in the use of echocardiography.  Eff Clin Pract. 1999;2(2):71-7510538479PubMedGoogle Scholar
36.
Hannan EL, Wu C, Chassin MR. Differences in per capita rates of revascularization and in choice of revascularization procedure for eleven states.  BMC Health Serv Res. 2006;6:35-4316542441PubMedGoogle ScholarCrossref
37.
Shaw LJ, Miller DD, Romeis JC, Kargl D, Younis LT, Chaitman BR. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease.  Ann Intern Med. 1994;120(7):559-5668116993PubMedGoogle ScholarCrossref
38.
Tobin JN, Wassertheil-Smoller S, Wexler JP,  et al.  Sex bias in considering coronary bypass surgery.  Ann Intern Med. 1987;107(1):19-253496029PubMedGoogle ScholarCrossref
39.
Hlatky MA, Pryor DB, Harrell FE Jr, Califf RM, Mark DB, Rosati RA. Factors affecting sensitivity and specificity of exercise electrocardiography: multivariable analysis.  Am J Med. 1984;77(1):64-716741986PubMedGoogle ScholarCrossref
40.
Kwok Y, Kim C, Grady D, Segal M, Redberg R. Meta-analysis of exercise testing to detect coronary artery disease in women.  Am J Cardiol. 1999;83(5):660-66610080415PubMedGoogle ScholarCrossref
41.
Lee CH, Tan M, Yan AT,  et al.  Use of cardiac catheterization for non–ST-segment elevation acute coronary syndromes according to initial risk: reasons why physicians choose not to refer their patients.  Arch Intern Med. 2008;168(3):291-29618268170PubMedGoogle ScholarCrossref
42.
Poses RM, Krueger JI, Sloman S, Elstein AS. Physicians' judgments of survival after medical management and mortality risk reduction due to revascularization procedures for patients with coronary artery disease.  Chest. 2002;122(1):122-13312114347PubMedGoogle ScholarCrossref
43.
Wennberg DE, Dickens JD, Biener L, Fowler FJ, Soule DN, Keller RB. Do physicians do what they say? the inclination to test and its association with coronary angiography rates.  J Gen Intern Med. 1997;12(3):172-1769100142PubMedGoogle Scholar
44.
Cabana MD, Rand CS, Powe NR,  et al.  Why don't physicians follow clinical practice guidelines? a framework for improvement.  JAMA. 1999;282(15):1458-146510535437PubMedGoogle ScholarCrossref
45.
McGlynn EA, Asch SM, Adams J,  et al.  The quality of health care delivered to adults in the United States.  N Engl J Med. 2003;348(26):2635-264512826639PubMedGoogle ScholarCrossref
46.
Peterson ED, Roe MT, Mulgund J,  et al.  Association between hospital process performance and outcomes among patients with acute coronary syndromes.  JAMA. 2006;295(16):1912-192016639050PubMedGoogle ScholarCrossref
47.
Rogers AM, Ramanath VS, Grzybowski M,  et al.  The association between guideline-based treatment instructions at the point of discharge and lower 1-year mortality in Medicare patients after acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) initiative in Michigan.  Am Heart J. 2007;154(3):461-46917719291PubMedGoogle ScholarCrossref
48.
Campione JR, Sleath B, Biddle AK, Weinberger M. The influence of physicians' guideline compliance on patients' statin adherence: a retrospective cohort study.  Am J Geriatr Pharmacother. 2005;3(4):229-23916503318PubMedGoogle ScholarCrossref
49.
Nallamothu BK, Rogers MAM, Chernew ME, Krumholz HM, Eagle KA, Birkmeyer JD. Opening of specialty cardiac hospitals and use of coronary revascularization in Medicare beneficiaries.  JAMA. 2007;297(9):962-96817341710PubMedGoogle ScholarCrossref
50.
Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending, part 2: health outcomes and satisfaction with care.  Ann Intern Med. 2003;138(4):288-29812585826PubMedGoogle ScholarCrossref
×